Amyloidosis Research & Education Fund

School of Medicine Department of Pathology and Laboratory Medicine

Amyloidosis is a group of diseases in which an abnormal protein called amyloid is produced. Because it negatively affects thousands of Americans each year, there’s an urgent need to identify and develop new ways to treat amyloidosis.

Unfortunately, funding from external sources is rare, making it hard for researchers to advance potential patient treatments. Gifts to this fund support basic, clinical, and translational research that could improve treatment and save lives.

Make a gift

Amyloidosis Research & Education Fund

School of Medicine Department of Pathology and Laboratory Medicine

Amyloidosis is a group of diseases in which an abnormal protein called amyloid is produced. Because it negatively affects thousands of Americans each year, there’s an urgent need to identify and develop new ways to treat amyloidosis.

Unfortunately, funding from external sources is rare, making it hard for researchers to advance potential patient treatments. Gifts to this fund support basic, clinical, and translational research that could improve treatment and save lives.

Additional Info

Amyloidosis wreaks havoc when amyloid fibers attach and deposit on organs, nerves, and other places in the body, affecting normal function.

Once considered a rare disease affecting less than 200,000 people, recent research has shown that amyloidosis might be underdiagnosed. It’s now thought, for example, that amyloidosis is a common cause of heart failure among older patients, and that over 4,000 people in the United States alone develop amyloid and light chain amyloidosis each year.

For more than 45 years, the IU School of Medicine’s Amyloid Center has been a prominent leader in the field. Over that period, the center described more than 25 hereditary mutations that can cause the disease. Research from the center’s scientists was also used to help develop a treatment for a form of the disease that damages the liver. That drug won approval from the Food and Drug Administration in 2018—a breakthrough in treating a fatal illness.

The School of Medicine wants to redouble its research efforts and train the next generation of experts and leaders in this area. That progress is only possible with investments in basic, clinical, and translational research—and because federal funding for this work is historically modest, gifts from donors like you are vital.

Your contribution can support skilled faculty members who have no outside funding and help stabilize resources for senior scientists so they can make steady progress. In short, your gift today will benefit countless patients and family members affected by amyloidosis, helping them lead healthier, happier lives.

Thank you for your support!

Your giving matters

Dr. Noel Dasgupta, Associate Professor of Clinical Medicine and Pathology & Laboratory Medicine.

Donations to the Amyloidosis Research and Education Fund are used to support resources that not only prolong life but also improve the quality of life for patients and family members affected by amyloidosis. Our team participates in state-of-the art research and treatment for patients with both hereditary and non-hereditary forms of amyloidosis.

Noel Dasgupta, MD, FACC Associate Professor of Clinical Medicine and Pathology & Laboratory Medicine

Important Disclosures

Please note, the name and purpose of the fund displayed on this page constitute the authorized description of the fund by the Indiana University Foundation, Inc. Your gift supports the fund as described herein.

Gifts will be administered by the Indiana University Foundation, Inc. which represents Indiana University, including the IU School of Medicine. This is not a gift to Indiana University Health, and the Indiana University Health Foundation will not play a role in administering these accounts.